US FDA approved Abbott Laboratories Inc.'s MitraClip transcatheter mitral valve repair system for select heart failure patients with clinically significant secondary, or functional, mitral regurgitation based on results of the COAPT trial, the company and agency announced March 14.
Functional MR Added To FDA-Approved Indication For Abbott's MitraClip
The new indication covers functional mitral regurgitation, also known as secondary mitral regurgitation, which represents two-to-three times as many patients as the primary mitral regurgitation population MitraClip is already labeled for. The approval is supported by results from the COAPT trial, the first randomized trial to show that a mitral-valve repair could improve outcomes in patients with secondary mitral regurgitation.
More from Approvals
More from Policy & Regulation
• By
Well over 200 European standards need harmonizing under the MDR. But only around 12% have been attended to so far.
• By
The medtech industry hopes to use a 90-day pause on tariffs to negotiate a “zero for zero” exemption. However, recent public comments from President Donald Trump suggest the health care sector may still be at risk.
• By
The architect of Germany’s hospital reform, Karl Lauterbach, will not be retained as health minister according to how the new CDU/CSU-SPD coalition government plans to spread the ministerial portfolios.